Mycapssa (Octreotide Acetate) Patent Expiration, LOE Window & CMS Spending
Mycapssa (Octreotide Acetate) by Chiesi Farmaceutici Spa: FDA Orange Book LOE 2040-12-28, 2 AB generics, $12.2M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Chiesi Farmaceutici Spa |
| FDA Application & Pathway | N208232 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2040-12-28 |
| Orange Book Patents (*PED Extensions) | 16 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 2 |
| 2024 CMS Total Public Spend | $12.2M |
| 2024 Medicare Part D Spend | $9.6M |
| 2024 Medicaid Spend | $2.6M |
| Reported Wholesale Price Change (CA SB 17) | 1 WAC filings (max 15.5% 2-yr change) |